Our Pipeline of saRNA-based Therapeutics:
Developing the Next Generation of RNA Drugs

Chimeron Bio’s pre-clinical pipeline consists of RNA entities in development across multiple disease areas including oncology, liver and kidney diseases, and infectious diseases.

curve seperator

Oncology

CB-101

CB-101 is an off-the-shelf personalized  RNA drug designed to engage the immune system by upregulating tumor neoantigens. Click to see how it works.

Dendritic Cell Activation

We are investigating ChaESAR RNA in dendritic cell activation-  convert dendritic cells into immunostimulatory antigen presenting cells to prime appropriate effector T-cells.


Liver Diseases

We are investigating ChaESAR RNA therapy for gene and metabolic disorders of the liver.


Kidney Diseases

We are investigating ChaESAR RNA therapy for gene and metabolic disorders of the kidney.


Infectious Diseases

We are investigating ChaESAR RNA therapy in liver abnormalities with a viral, bacterial, and parasitic etiology.

What Makes These Medicines Compelling?

See how we’re building on the modern science of RNA and our novel technology to develop saRNA therapies that can achieve superior patient response at a lower dose.

Explore Our Technology